Etrolizumab

Summary

Etrolizumab (CHEMBL1743015) is a phase-3 clinical-stage antibody targeting ITGB7; indicated across 2 conditions including ulcerative colitis and crohn disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (ITGB7)
• Indications: 2 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743015
Name	Etrolizumab
Type	Antibody
Max phase	3

Also known as: Anti-.beta.7, Anti-Beta7, Anti-Beta7 Pro145223, Etrolizumab, PRO-145223, PRO145223, RG-7413, Rhumab .beta.7, RHUMAB-BETA7, RHUMABBETA7, rhuMAb beta7, ETROLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ITGB7	integrin, beta 7 subunit	Binding		1%	P26010
	integrin α4β7	Binding	10.12
	integrin αEβ7	Inhibition

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ITGB7.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Adaptive Immune System	1	ITGB7
Extracellular matrix organization	1	ITGB7
Immune System	1	ITGB7
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	ITGB7
Integrin cell surface interactions	1	ITGB7

Dominant GO biological processes

GO term	Targets
immune response in gut-associated lymphoid tissue	1
cell-matrix adhesion involved in ameboidal cell migration	1
cell adhesion	1
cell-matrix adhesion	1
integrin-mediated signaling pathway	1
cell adhesion mediated by integrin	1
heterotypic cell-cell adhesion	1
substrate adhesion-dependent cell spreading	1
receptor clustering	1
leukocyte migration	1
leukocyte tethering or rolling	1
T cell migration	1
cell-cell adhesion	1
symbiont entry into host cell	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ulcerative colitis	3	MONDO:0005101	EFO:0000729
Crohn disease	3	MONDO:0005011	EFO:0000384

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	7
PHASE1	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02118584	PHASE3	TERMINATED	Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
NCT02136069	PHASE3	COMPLETED	A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
NCT02163759	PHASE3	COMPLETED	A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02165215	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02171429	PHASE3	COMPLETED	A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02394028	PHASE3	COMPLETED	A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn’s Disease
NCT02403323	PHASE3	TERMINATED	Open-Label Extension and Safety Study for Participants With Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
NCT01336465	PHASE2	COMPLETED	Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis
NCT01461317	PHASE2	COMPLETED	Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
NCT00694980	PHASE1	COMPLETED	A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
NCT02629744	PHASE1	COMPLETED	A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants
NCT02996019	PHASE1	COMPLETED	A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)
NCT03478956	PHASE1	TERMINATED	A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn’s Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).